-
ProPhase faces NASDAQ delisting
DOYLESTOWN, Pa. — ProPhase Labs on Tuesday announced that it received a letter from the NASDAQ Stock Market indicating that the company no longer is in compliance with NASDAQ listing rules because the closing bid price per share of its common stock has dropped below $1 per share for 30 consecutive trading days.
ProPhase will have until Dec. 27 to push its stock price above $1 for a minimum of 10 consecutive trading days to regain compliance or risk being delisted.
-
New niches fuel multivitamins
Findings from the past year show that vitamin sales have been stronger than most other health and beauty categories. The recent emphasis placed by vitamin and nutritional supplement manufacturers on new multivitamin brands has delivered positive results. SymphonyIRI Group reported that, in the 24 weeks ended May 15, multivitamins outperformed the total vitamin category.